The embargo on all abstracts accepted to the 2020 Genitourinary Cancers Symposium will lift at 5:00 p.m. ET on Monday, February 10, 2020.
Attend the Meeting in Person
Media registration for the 2020 Genitourinary Cancers Symposium is now open. At this time, you can visit ASCO's Media Headquarters to apply for media credentials*, register to attend an upcoming meeting, and access embargoed meeting information. For questions about how to navigate the site, please contact ASCO Media Registration.
*If you attended the 2019 ASCO Annual Meeting or covered the meeting remotely, you have already been credentialed by ASCO and will have access to the embargoed meeting information. You only have to register if you want to attend the Genitourinary Cancers Symposium in person in San Francisco.
Access Embargoed Information
Embargoed meeting information will be made available to credentialed media through ASCO's Media Headquarters. Once your media credentials are approved, you will receive email notifications when embargoed information has been posted.
- Coming soon!
- View a recording of the February 11 presscast, featuring three studies from the 2019 Genitourinary Cancers Symposium.
- Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men With Metastatic Prostate Cancer
ALEXANDRIA, Va. – A single-arm, phase II trial in men with PSMA-positive metastatic, castration-resistant prostate cancer (mCRPC) that progressed despite standard therapies, found that in the majority of men, the cancers were responsive to treatment with a novel, targeted radiation therapy called Lutetium-177 PSMA-617 (LuPSMA). This is the first prospective study of LuPSMA, part of a potential new class of treatments for men with metastatic prostate cancer. According to the researchers, men receiving the medication lived a median of 13.3 months after treatment, longer than the average 9-month survival time for men with this stage of disease. Read the full release.
- African-American Men With Advanced Prostate Cancer Live Longer Compared With White Men When Treated With Newer Hormone Therapies
A large, retrospective study analyzing five years of data from the Veterans Health Administration (VHA) found that African-American men with metastatic castration-resistant prostate cancer (mCRPC) who were treated with newer prostate cancer drugs abiraterone acetate (Zytiga) or enzalutamide (Xtandi) – and who had not received prior chemotherapy – lived 20% longer compared with white men who received the same treatment. Read the full release.
- Pembrolizumab Plus Axitinib Extended Overall Survival and Progress-Free Survival Versus Current Standard Treatment for Advanced Kidney Cancer
ALEXANDRIA, Va. – Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy pembrolizumab (Keytruda) and the VEGF-targeted tyrosine kinase inhibitor axitinib (Inlyta) extended both overall survival and progression-free survival for patients with clear-cell metastatic renal cell carcinoma (mRCC), compared with the current standard of care, sunitinib (Sutent). Read the full release.